Literature DB >> 33264542

Hydroxychloroquine with or without Azithromycin in Covid-19. Reply.

Alexandre B Cavalcanti1, Otávio Berwanger2, Fernando G Zampieri3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33264542     DOI： 10.1056/NEJMc2031780

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.

Authors:  Silvano Wendel; Kevin Land; Dana V Devine; James Daly; Renée Bazin; Pierre Tiberghien; Cheuk-Kwong Lee; Satyam Arora; Gopal K Patidar; Kamini Khillan; Willem Martin Smid; Hans Vrielink; Adaeze Oreh; Arwa Z Al-Riyami; Salwa Hindawi; Marion Vermeulen; Vernon Louw; Thierry Burnouf; Evan M Bloch; Ruchika Goel; Mary Townsend; Cynthia So-Osman
Journal:  Vox Sang       Date:  2021-03-27       Impact factor: 2.996

2.  Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study.

Authors:  Sandro Luigi Di Domenico; Daniele Coen; Marta Bergamaschi; Valentina Albertini; Leonardo Ghezzi; Michela Maria Cazzaniga; Valeria Tombini; Riccardo Colombo; Nicolò Capsoni; Tommaso Coen; Katia Barbara Cazzola; Marina Di Fiore; Laura Angaroni; Marco Alberto Strozzi
Journal:  Intern Emerg Med       Date:  2020-11-11       Impact factor: 3.397

3.  Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study.

Authors:  Kin Wah Fung; Fitsum Baye; Joan Kapusnik-Uner; Clement J McDonald
Journal:  Drugs Real World Outcomes       Date:  2021-02-10

4.  Blockage of interleukin-1β with canakinumab in patients with Covid-19.

Authors:  Lorenza Landi; Claudia Ravaglia; Emanuele Russo; Pierluigi Cataleta; Maurizio Fusari; Andrea Boschi; Diana Giannarelli; Francesca Facondini; Ilaria Valentini; Ilaria Panzini; Luigi Lazzari-Agli; Paolo Bassi; Elisa Marchionni; Rossella Romagnoli; Raffaella De Giovanni; Marina Assirelli; Federica Baldazzi; Fabio Pieraccini; Giovanna Rametta; Lucia Rossi; Luca Santini; Ivana Valenti; Federico Cappuzzo
Journal:  Sci Rep       Date:  2020-12-11       Impact factor: 4.379

5.  An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.

Authors:  Álvaro Réa-Neto; Rafaella Stradiotto Bernardelli; Bruna Martins Dzivielevski Câmara; Fernanda Baeumle Reese; Marcos Vinicius Oliveira Queiroga; Mirella Cristine Oliveira
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

6.  Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).

Authors:  Horst Olschewski; Ernst Eber; Brigitte Bucher; Klaus Hackner; Sabin Handzhiev; Konrad Hoetzenecker; Marco Idzko; Walter Klepetko; Gabor Kovacs; Bernd Lamprecht; Judith Löffler-Ragg; Michael Meilinger; Alexander Müller; Christian Prior; Otmar Schindler; Helmut Täubl; Angela Zacharasiewicz; Ralf Harun Zwick; Britt-Madelaine Arns; Josef Bolitschek; Katharina Cima; Elisabeth Gingrich; Maximilian Hochmair; Fritz Horak; Peter Jaksch; Roland Kropfmüller; Andreas Pfleger; Bernhard Puchner; Christoph Puelacher; Patricia Rodriguez; Helmut J F Salzer; Peter Schenk; Ingrid Stelzmüller; Volker Strenger; Matthias Urban; Marlies Wagner; Franz Wimberger; Holger Flick
Journal:  Wien Klin Wochenschr       Date:  2022-04-21       Impact factor: 2.275

7.  Safety and Efficacy of Ivermectin for the Prevention and Treatment of COVID-19: A Double-Blinded Randomized Placebo-Controlled Study.

Authors:  Nasikarn Angkasekwinai; Pinyo Rattanaumpawan; Methee Chayakulkeeree; Pakpoom Phoompoung; Pornpan Koomanachai; Sorawit Chantarasut; Walaiporn Wangchinda; Varalak Srinonprasert; Visanu Thamlikitkul
Journal:  Antibiotics (Basel)       Date:  2022-06-12

8.  Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).

Authors:  Jakob J Malin; Christoph D Spinner; Uwe Janssens; Tobias Welte; Steffen Weber-Carstens; Gereon Schälte; Petra Gastmeier; Florian Langer; Martin Wepler; Michael Westhoff; Michael Pfeifer; Klaus F Rabe; Florian Hoffmann; Bernd W Böttiger; Julia Weinmann-Menke; Alexander Kersten; Peter Berlit; Marcin Krawczyk; Wiebke Nehls; Falk Fichtner; Sven Laudi; Miriam Stegemann; Nicole Skoetz; Monika Nothacker; Gernot Marx; Christian Karagiannidis; Stefan Kluge
Journal:  Infection       Date:  2021-07-06       Impact factor: 3.553

Review 9.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.